Editas Medicine will eliminate about 180 roles after failing to find a commercial partner for an experimental sickle cell ...

ICER reports $800M+ annual US cost increase from 5 drugs (Biktarvy, Darzalex, Entresto, Cabometyx, Xeljanz) with 2023 price ...

Keros Therapeutics halts two dosing arms of cibotercept Phase 2 trial due to pericardial effusion safety concerns; continues ...

Demis Hassabis has no interest in a laboratory. The Nobel Prize-winning artificial intelligence pioneer is betting big on ...

Former Padlock shareholders sue Bristol Myers Squibb over alleged unpaid milestone payments for antibody BMS-986454, claiming ...

Pfizer touts Ibrance’s status as a standard of care in HR-positive, HER2-negative metastatic breast cancer. Now the company ...

Lonza CEO Wolfgang Wienand plans to exit capsules/health ingredients market and restructure into three business units, with ...

Eli Lilly partners with telehealth company Ro to distribute discounted Zepbound vials at $399/month, while competitor Novo ...

End­points News has once again reached out to a lengthy ros­ter of biotech ex­ecs to take their pulse on what’s ahead for the ...

Illumina exec Vik Vaz as CEO to advance biological detection tech for drug research. The company uses what it calls ...

Corcept Therapeutics' dazucorilant fails Phase 2 ALS trial after missing primary endpoint, following October's Cushing's ...

Columvi combo in DLBCL, while AnaptysBio's ANB032 fails in atopic dermatitis. Essential Pharma gets €1.2B financing deal.